Roche’s Genentech has inked a deal with Repertoire Immune Medicines aimed at discovering and developing T-cell-targeted ...

Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new ...

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Repertoire will obtain an upfront payment of $35m from Genentech, with the potential for up to $730m in additional milestones ...

The BriefBay Area biotech giant Genentech is offering menopause support for employees.The program seeks to personalized ...

Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech ...

In recent days, Boston Scientific announced a forthcoming CFO change, a Cambridge biotech undertook a 1-for-20 reverse stock ...

About Genentech in neuroscience Neuroscience is a major focus of research and development at Genentech and Roche. Our goal is to pursue groundbreaking science to develop new treatments that help ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that the New England Journal of Medicine has published a detailed analysis of the Phase III CENTERSTONE trial of Xofluza ...

SOUTH SAN FRANCISCO, Calif., April 03, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data were presented at the AD/PD 2025 ...

Developing new medications can take years. But computational biologist Aviv Regev says AI-powered cell mapping is ...